PAREXEL International Announces Xavier Flinois as Incoming President of Perceptive Informatics

BOSTON, Jan. 22, 2013 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has selected Xavier Flinois to succeed Steve Kent as president of Perceptive Informatics, PAREXEL’s technology division. Steve Kent, who decided to leave the company for personal reasons, was involved in the search for his successor and will remain with the Company for several months to help with the transition.

Mr. Flinois joins PAREXEL with more than 20 years of experience in the technology and healthcare IT sector. Most recently, Mr. Flinois was chief executive officer of Clinical Solutions, a leading supplier of flexible evidence-based decision support and clinical software solutions to the healthcare industry. Prior to Clinical Solutions, Mr. Flinois was founder and CEO of Houat Partners, a consulting and investment boutique. He also served as CEO of SchlumbergerSema and was a member of the management board of AtosOrigin, both international IT services companies.

“We welcome Xavier to the PAREXEL team, and look forward to drawing upon his extensive industry experience to bring Perceptive Informatics’ track record of innovation to new heights and to enhance its suite of hosted software-as-a-service (SaaS) applications for our clients,” said Mark A. Goldberg, President and Chief Operating Officer, PAREXEL. “We thank Steve Kent for his important contributions to PAREXEL over the past four years, during which time Perceptive Informatics has become an industry-leading eClinical solutions provider known for developing next-generation technologies aligned to accelerate clinical development.”

Mr. Flinois holds a Master’s degree in Science from Ecole Polytechnique and a Master’s degree in Engineering from Ecole des Ponts et Chaussees. The Perceptive Informatics global senior management team will report to Mr. Flinois, effective immediately. He will also serve as a member of PAREXEL’s Business Review Committee, the Company’s most senior leadership group.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 73 locations throughout 51 countries around the world, and has approximately 14,000 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2012 as filed with the SEC on November 8, 2012, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark and PAREXEL and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

SOURCE PAREXEL International Corporation